BC3 Technologies targets more than 500% revenue growth in 2026

Baltimore-based MedTech company said first-half sales topped $1 million as demand for its SEAL Hemostatic Wound Spray expanded across consumers, first responders and international buyers.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.